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TORC1Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterised by the development of
hamartomas in a variety of organs and tissues. The disease is caused by mutations in either the TSC1 gene on
chromosome 9q34, or the TSC2 gene on chromosome 16p13.3. The TSC1 and TSC2 gene products, TSC1 and
TSC2, interact to form a protein complex that inhibits signal transduction to the downstream effectors of the
target of rapamycin complex 1 (TORC1). Here we investigate TSC1 structure and function by analysing a
series of truncated TSC1 proteins. We identify speciﬁc regions of the protein that are important for TSC1
stability, localisation, interactions and function.EB, ras homolog expressed in
p70 S6 kinase; GAP, GTPase
31 10 7044736.
.
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Tuberous sclerosis complex (TSC) is an autosomal dominant
disorder characterised by the development of hamartomas in a
variety of organs and tissues, including the brain, skin and kidneys [1].
Mutations in either the TSC1 gene on chromosome 9q34 [2], or the
TSC2 gene on chromosome 16p13.3 [3] cause TSC.
The TSC1 and TSC2 gene products, TSC1 and TSC2, interact to form a
protein complex [4]. TSC2 contains a GTPase activating protein (GAP)
domain, and the TSC1–TSC2 complex has been shown to have GAP
activity for a GTPase called ras homolog expressed in brain (RHEB).
The TSC1–TSC2 complex stimulates the hydrolysis of RHEB-bound
GTP to GDP, thereby inhibiting the RHEB-GTP-dependent stimulation
of the target of rapamycin complex 1 (TORC1) [5]. TORC1 regulates a
wide array of cellular processes, including transcription, translation
and autophagy [6]. Inactivation of the TSC1–TSC2 complex results in
the phosphorylation of TORC1 targets, including p70 S6 kinase (S6K)
and elongation factor 4E binding protein 1 and, consequently,
increased protein synthesis and cell growth [6]. TSC1 has limited
homology with other proteins [2] and the exact role of TSC1 in the
TSC1–TSC2 complex is not completely clear. Some studies have shown
that TSC1 is required for TSC2 GAP activity [7–9], while others suggestthat TSC1 is not essential for GAP activity but is necessary to maintain
the stability, activity and correct intracellular localisation of the TSC1–
TSC2 complex [10,11]. TSC1 has been shown to be involved in
recruitment of the TSC1–TSC2 complex to cell membranes [12] and
may integrate multiple inputs to help regulate TORC1 activity, or
perform other, independent functions [13].
In the absence of TSC2, over-expressed TSC1 forms Triton X100-
insoluble aggregates or inclusions due to interactions between the coiled
coil regions (amino acids 719–998) of different TSC1 molecules [14].
Coexpression of TSC2prevents the formation of these inclusions, resulting
in a shift of TSC1 to Triton X100-soluble cell lysate fractions [15]. Stable
TSC1–TSC2 complexes can be immunoprecipitated from these cell
fractions, demonstrating that TSC2 acts as a molecular chaperone,
maintaining TSC1 in a stable cytosolic form [14]. Recently, we identiﬁed
TSC1 amino acid substitutions in TSC patients that prevented TSC1
inclusion formation in vitro [16,17]. Surprisingly, none of these changes
mapped to the coiled coil region, indicating that other regions of TSC1 are
also important for the expression and localisation of the protein.
To gain additional insight into the structure and function of TSC1,
we compared full-length TSC1 to a series of TSC1 N- and C-terminal
truncation proteins. Our in vitro analysis demonstrates that the N-
terminal region is important for TSC1 stability and that both the N-
terminal and coiled coil regions are required for TSC1 aggregation.
Furthermore, we show that multiple regions of TSC1 are required for
binding TSC2 and that some TSC1 truncations can co-operate with
TSC2 to inhibit TORC1 activity. This information will be useful for the
functional characterisation of unclassiﬁed TSC1 variants identiﬁed in
individuals with TSC.
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2.1. Generation of constructs and antisera
To derive expression constructs encoding myc-tagged TSC1 C-
terminal truncations a KpnI site was introduced into a full-length
myc-tagged TSC1 expression construct by site-directed mutagenesis
(QuikChange, Stratagene, La Jolla, CA, U.S.A.). After digestion with
KpnI to excise the 3′ portion of the TSC1 open reading frame (ORF), the
vector and remaining ORF was re-circularised so that the epitope tag
remained in-frame with the last codon of the truncated TSC1 ORF. N-
terminal truncations were derived in a similar way. A NheI site was
introduced to allow excision of the 5′ portion of the TSC1 ORF. In each
case the complete open reading frame of the new construct was
veriﬁed by sequence analysis. Expression constructs were derived for
4 C-terminal truncation proteins: Q900 (TSC1 amino acids 1–900,
molecular mass 100 kDa), R692 (amino acids 1–692, 80 kDa), R509
(amino acids 1–509, 60 kDa) and T339 (amino acids 1–339, 35 kDa);
one N-terminal truncation protein, M351 (amino acids 351–1164,
100 kDa), and one truncation protein, M351-Q900, lacking both
termini (amino acids 351–900, 65 kDa). The pathogenic L117P and
M224R missense changes were introduced by site-directed mutagen-
esis, as described previously [15]. An overview of the expressed TSC1
truncation proteins is shown in Fig. 1. Other constructs used in this
study have been described elsewhere [4,15,18].
Antibodies were purchased from Cell Signaling Technology
(Danvers, MA, U.S.A.), except for a mouse monoclonal antibody
against TSC2 which was purchased from Zymed Laboratories (San
Francisco, CA, U.S.A.), or were described previously [4]. Secondary
antibodies for infra-red detection proteins on immunoblots were
obtained from Li-Cor Biosciences (Lincoln, NE, U.S.A.).Fig. 1. TSC1 truncation proteins. Schematic diagram illustrating the TSC1 truncation proteins
acids 127–144), coiled coil region (amino acids 719–998), and the L117P and M224R miss
positions of the ﬁrst and last amino acids, relative to the full-length protein (top).2.2. Immunoblot analysis of cells over-expressing TSC1 truncations
HEK 293T cells in 3.5 cm dishes were transfected with expression
constructs using polyethylenimine (Polysciences Inc., Warrington, PA,
U.S.A.)[19]. Twenty-four hours after transfection the cells were washed
with cold phosphate buffered saline (PBS) and lysed in 0.15 ml lysis
buffer (50 mM Tris–HCl (pH 7.5), 100 mM NaCl, 50 mM NaF, 1% Triton
X100 and a protease inhibitor cocktail (Complete, Roche Molecular
Biochemicals)) for 10 min on ice. The cell lysates were cleared by
centrifugation (10,000 g for 10 min at 4 °C) and the supernatant (Triton
X100-soluble) and pellet (Triton X100-insoluble) fractions were
recovered. The pellet fractions were resuspended in 0.15 ml lysis buffer
and sonicated at 12 μm for 15 s prior to immunoblot analysis using the
Criterion SDS-PAGE system (BioRad, Hercules, CA, U.S.A.). Protein
expression levels were estimated by near infra-red detection and
quantiﬁcation of the blotted proteins on an Odyssey™ scanner (Li-Cor
Biosciences).
To estimate the effect of the TSC1 truncation proteins on S6K T389
phosphorylation HEK 293T cells were transfected with a 4:2:1 mixture
of the TSC1, TSC2 and S6Kexpression constructs andharvested as above.
The Triton X100-soluble fractionswere analysed by immunoblotting, as
described previously [16,17].
2.3. Immunoﬂuorescent detection of TSC1 truncations
HEK 293T cells were seeded onto glass cover slides coated with
poly-L-lysine (Sigma-Aldrich, Carlsbad, CA, U.S.A.), transfected and
processed for immunoﬂuorescent microscopy as described previ-
ously [16]. Fixed, permeabilised cells were incubated with a primary
mouse monoclonal antibody speciﬁc for the myc epitope tag,
followed by a cyanine (Cy2)-coupled secondary antibody (DAKO,used as part of this study. The positions of the predicted transmembrane domain (amino
ense mutations identiﬁed in individuals with TSC are indicated. Numbers indicate the
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La Jolla, CA, U.S.A.) and studied using a Leica DMRXAmicroscope and
Image Pro-Plus version 6 image analysis software.
2.4. Coimmunoprecipitation of TSC2 with the TSC1 truncations
Immunoprecipitations were performed using the Triton X100-
soluble cell lysate fractions. EZ Red anti-myc afﬁnity beads (Sigma-
Aldrich) were pre-equilibrated in lysis buffer prior to incubation with
the cell lysates for 3 h at 4 °C with gentle rotation. The beads were
washed at least 3 times with N20-fold excess of lysis buffer per wash
step. Beads were recovered by gentle centrifugation (1000 g for 15 s at
4 °C) between each wash step, and resuspended in sample buffer prior
to immunoblot analysis.
3. Results
3.1. TSC1 truncation proteins
We derived expression constructs for 4 C-terminal TSC1 truncations
that we called: Q900, R692, R509 and T339. The Q900 truncation
consists of TSC1 amino acids 1–900 and corresponds to a TSC1
c.2919CNT (p.Q900X) mutation, the most distal TSC1 mutation
identiﬁed in our patient cohort [20]. We identiﬁed this mutation in 2
unrelated cases of TSC. Clinical data was available for one of these
individuals (Table 1). The R692 and R509 truncations consist of amino
acids 1–692 and 1–509 respectively, and correspond to the TSC1
c.2295CNT and c.1746CNT mutations. Together these 2 mutations
account for N5% of the TSC1 variants listed in the Leiden Open Tuberous
Sclerosis Complex Variation Database [21]. We identiﬁed the TSC1
c.2295CNT mutation in 6 families in our cohort, and in 5 cases had
clinical data on one or more individuals (Table 1).We identiﬁed 6 cases
with the TSC1 c.1746CNT mutation in our cohort. Clinical data was
available for one individual (Table 1). The T339 truncation corresponds
to a TSC1 c.1015dupA mutation identiﬁed in an individual with very
mild peripheral features of TSC, epilepsy and cognitive disturbances
(Table 1) (P. de Vries, personal communication).
In addition to the C-terminal truncations, we expressed 2 proteins
lacking 350 amino acids from the N-terminus of TSC1. Truncation
protein M351 consisted of TSC1 amino acids 351–1164, and
truncation protein M351-Q900 consisted of amino acids 351–900. A
schematic overview of the truncation proteins is shown in Fig. 1.
Full-length TSC1 and the TSC1 truncation proteinswere expressed as
fusion proteins containing a C-terminal myc epitope tag. This tag did not
interfere with either the TSC1–TSC2 interaction, or with the function of
the TSC1–TSC2 complex [15–19]. We compared the relative expression
levels of the truncation proteins in the Triton X100-soluble andTable 1
Clinical ﬁndings in individuals with the TSC1 c.2919CNT (p.Q900X), TSC1 c.2295CNT (p.
R692X) and TSC1 c.1015dupA (p.T339X) mutations.
Case Mutation Renal Other Skin Neurological Brain
1 c.2919CNT RC – HM, FA, SP E, MR, BD SEN, CT
2 c.2295CNT – CR HM E, MR SEN, CT
3 c.2295CNT – – HM E SEN, CT
4.1 c.2295CNT – – FA, HM E SEGA
4.2 c.2295CNT – – UF E SEN
5 c.2295CNT – CR HM, SP E, BD –
6 c.2295CNT – DP, RP FA, UF E, BD SEN, CT
7 c.1746CNT RC CR – – SEN, CT
8 c.1015dupA – WPW HM E, BD –
Key: –, not present, or not recorded; RC, renal cysts; CR, cardiac rhabdomyoma; DP,
dental pit; RP, retinal phakoma; WPW, Wolff–Parkinson–White syndrome; HM,
hypomelanotic macule; SP, shagreen patch; UF, ungual ﬁbroma; FA, facial
angioﬁbroma; E, epilepsy; MR, mental retardation; BD, behavioural disturbance; SEN,
subependymal nodule; CT, cortical tuber; and SEGA, subependymal giant cell
astrocytoma.-insoluble fractions by immunoblotting. Full-length TSC1 and the Q900
truncation were detected predominantly in the Triton X100-insoluble
fraction, while the remaining truncation proteins were detected
predominantly in the soluble fraction (Fig. 2A,C).3.2. TSC1 truncation prevents aggregate formation
The Q900 truncation protein localised to cytoplasmic punctate
inclusions or aggregates in HEK 293 T cells (Fig. 3A) and was detected
predominantly in Triton X100-insoluble cell lysate fractions, similar to
full-length TSC1 (Fig. 2A,C). In contrast, truncation proteins R692, R509
and T339 that lack the entire coiled coil region, and theM351 truncation
protein, that contains the coiled coil region but lacks the TSC1 N-
terminal, were detected predominantly in Triton X100-soluble cell
lysate fractions (Fig. 2A,C) and did not form cytoplasmic inclusions
(Fig. 3C,D, and data not shown)We concluded that the coiled coil region
was necessary but not sufﬁcient for aggregate formation.Fig. 2. Immunoblot analysis of TSC1 truncation proteins. Wild-type myc-tagged TSC1
(TSC1) and the myc-tagged truncations were over-expressed in HEK 293T cells. Triton
X100-soluble and -insoluble cell lysate fractions were separated on 4–12% gradient
SDS-PAGE gels, blotted and incubated with a monoclonal mouse antibody against the
myc epitope tag. (A) Immunoblot of Triton X100-soluble and -insoluble cell lysate
fractions. Bands marked with an asterisk (*) are due to leakage of the signal from the
R692 truncation. (B) Total expression of the TSC1 truncation proteins. Truncation
protein levels were quantiﬁed in at least 3 separate experiments, and the mean
expression levels, relative to full-length myc-tagged TSC1, were derived. Standard
deviations are indicated. (C) Relative expression of the TSC1 truncations in Triton X100-
soluble and -insoluble cell lysate fractions. The signal detected in the soluble fraction
was divided by the total signal (soluble+insoluble) for each protein in at least 3
separate experiments. Standard deviations are indicated.
Fig. 3. Immunoﬂuorescence analysis of TSC1 truncation protein expression. Transfected HEK 293T cells expressing the different truncation proteins were ﬁxed and incubated with an
antibody against the myc epitope tag. (A) Punctate, cytoplasmic localisation of truncation protein Q900. (B) Punctate, cytoplasmic localisation of full-length TSC1. (C) Diffuse,
cytoplasmic localisation of truncation protein M351. (D) Diffuse, cytoplasmic localisation of truncation protein R509.
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Pathogenic aminoacid substitutions in theN-terminal regionof TSC1
prevent TSC1 aggregation and reduce expression levels in vitro [16,17].
To determine whether this destabilisation is due to effects on local
protein folding, or due to long-range interactions between theN- and C-
terminal regions of TSC1, a pathogenic N-terminal amino acid
substitution (M224R) [17] was introduced into the R692 truncation
protein. that lacks the C-terminal region (amino acids 693–1164). As
shown in Fig. 4, theM224Rsubstitution reduced theamountofboth full-
length TSC1 and theR692 truncation detected in theTritonX100 soluble
fraction, demonstrating that theM224R substitutionhad the sameeffect
irrespective of the presence or absence of amino acids 693–1164. We
concluded that the low expression levels of TSC1 missense mutants
[16,17,22] are more likely due to autonomous effects on the N-terminal
region than disruption of long-range interactions with the TSC1 C-
terminal, containing the predicted coiled coil regions.
3.4. TSC1 truncation reduces the stability of the TSC1–TSC2 complex
The formation of stable, Triton X100-soluble TSC1–TSC2 complexes
prevents TSC1 aggregation [14]. We coexpressed TSC2 with the TSC1
truncations in HEK 293T cells and estimated the proportions of the
expressed proteins in the Triton X100-soluble fractions (Fig. 5A,C). As
expected, the proportion of full-length TSC1 detected in the TritonX100-
soluble fraction was increased by coexpression of TSC2, as estimated by
immunoblotting (compare Figs. 2C and 5C). TSC2 coexpression had a
similar effect on theQ900 truncation, increasing the proportion detected
in the soluble fraction (compare Figs. 2C and 5C).
To investigate whether the TSC1 truncation proteins interacted
directly with TSC2, we coexpressed TSC2 with the different TSC1
truncations and immunoprecipitated the truncation proteins from the
Triton X100-soluble cell lysate fractions. We determined whether TSC2
was coimmunoprecipitated by immunoblotting. As shown in Fig. 6, allthe TSC1 truncationproteinswere immunoprecipitated efﬁciently, even
those that were expressed at low levels. TSC2 coimmunoprecipitated
with TSC1 and with the M351 and Q900 truncations, and to a lesser
extent with the R692 and R509 truncations. TSC2 was not coimmuno-
precipitated with the M351-Q900 or T339 truncations or with a control
protein (myc-tagged β-lactamase).
The interaction detected between the Q900 truncation and TSC2
was consistent with the observed shift of the Q900 truncation from
the insoluble to the soluble fraction (compare Figs. 2 and 5). However,
the TSC2–Q900 interaction appeared weaker than that between TSC2
and full-length TSC1 (Fig. 6D). Similarly, TSC2 was coimmunopreci-
pitated with the M351 truncation, but less efﬁciently than with full-
length TSC1 (Fig. 6D). Therefore, we concluded that multiple regions
of TSC1 are necessary for the interaction with TSC2 and to form a
stable TSC1–TSC2 complex.
3.5. The central region of TSC1 is involved in TSC1–TSC1 interactions
Interactions between the TSC1 coiled coil regions cause TSC1
aggregation [14]. We sought additional evidence for TSC1–TSC1
interactions by coimmunoprecipitation. As shown in Fig. 7, the myc-
tagged TSC1 truncations were immunoprecipitated from Triton X100-
soluble fractions. Coimmunoprecipitated full-length (untagged) TSC1
was detected by immunoblotting. TSC1 was coimmunoprecipitated
with the M351 and M351-Q900 truncations that contain part or all of
the coiled coil region, and, to a lesser extent, by the R509 and R692
truncations, that do not (Fig. 7A,C). TSC1 was not detected in the T339
and Q900 immunoprecipitates, or in the control immunoprecipitate.
We were unable to detect stable TSC1–Q900 complexes by coimmu-
noprecipitation because both full-length TSC1 and the Q900 trunca-
tion localised predominantly to the Triton X100-insoluble cell lysate
fractions. We concluded that in addition to the coiled coil region, the
central region of TSC1 (amino acids 351–509) is involved in the TSC1–
TSC1 interaction.
Fig. 5. Immunoblot analysis of coexpression of TSC2 and the TSC1 truncation proteins.
Wild-type myc-tagged TSC1 (TSC1) and the myc-tagged truncations were coexpressed
with TSC2 in HEK 293T cells. Triton X100-soluble and -insoluble cell lysate fractions
were separated on 4–12% gradient SDS-PAGE gels, blotted and incubated with
antibodies speciﬁc for TSC2 and the myc epitope tag. (A) Immunoblot of Triton
X100-soluble and -insoluble cell lysate fractions prepared from cells coexpressing TSC2
and the TSC1 truncation proteins. (B) Effect of TSC2 coexpression on expression levels
of the TSC1 truncation proteins. Protein levels were quantiﬁed as in Fig. 2B. Standard
deviations are indicated. (C) Effect of TSC2 coexpression on the relative expression
levels of the TSC1 truncation proteins in Triton X100-soluble and -insoluble cell lysate
fractions. Expression levels were quantiﬁed as in Fig. 2C. Standard deviations are
indicated.
Fig. 4. Effect of the pathogenic M224R amino acid substitution on expression of the
R692 truncation protein. Wild-type myc-tagged TSC1 (TSC1), the TSC1-M224R mutant,
the R692 truncation protein, and the R692-M224Rmutant truncationwere coexpressed
with TSC2 in HEK 293T cells. Triton X100-soluble and -insoluble cell lysate fractions
were separated on 4–12% gradient SDS-PAGE gels, blotted and incubated with
antibodies speciﬁc for TSC2 and the myc epitope tag. (A) Immunoblot showing
expression of full-length TSC1 and the R692 truncation protein compared to the TSC1-
M224R and R692-M224R mutants. The levels of the TSC1-M224R and R692-M224R
mutants detected in the Triton X100 soluble fraction is reduced compared to wild-type
TSC1 and the R692 truncation. Coexpressed TSC2 is shown as a control for transfection
efﬁciency. (B) Total expression of the TSC1-M224R and R692-M224R mutants. Protein
levels in the Triton X100 soluble and insoluble fractions were quantiﬁed and summed
in at least 3 separate experiments, and the mean expression levels, relative to full-
length myc-tagged TSC1, were calculated. Standard deviations are indicated. (C)
Relative expression of the TSC1-M224R and R692-M224R mutants in Triton X100-
soluble and -insoluble cell lysate fractions. The signal detected in the soluble fraction
was divided by the total signal (soluble+insoluble) for each protein in at least 3
separate experiments. Standard deviations are indicated.
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To determine whether the TSC1 truncations could affect the TSC2-
dependent inhibition of S6K-T389 phosphorylation, TSC2, S6K and the
TSC1 truncations, were expressed in HEK 293T cells and the T389
phosphorylation status of S6K was estimated by immunoblotting, as
shown in Fig. 8. The R509 truncation was not included in this analysis
as it comigrated with S6K, making it difﬁcult to detect and quantify
separate R509 and S6K signals.
Although the expression levels of the different TSC1 truncation
proteins were variable (Fig. 8B), the expression levels of TSC2 (Fig. 8C)and S6K (Fig. 8E) were relatively constant. This indicated that
coexpression of the different TSC1 truncations did not affect TSC2
expression levels. In cells coexpressing TSC2 and full-length TSC1,
S6K-T389 phosphorylation was reduced approximately 7-fold com-
pared to cells expressing neither protein, or to cells expressing TSC1
only (Fig. 8D). Expression of TSC2 only (without TSC1) was less
effective than coexpression of TSC1 and TSC2: S6K-T389 phosphor-
ylationwas approximately 5-fold higher in TSC2 expressing cells, than
in TSC1–TSC2 expressing cells. Coexpression of the TSC1 T339 and
M351-Q900 truncations did not affect the ability of TSC2 to reduce
S6K-T389 phosphorylation (Fig. 8D). In contrast, coexpression of TSC2
with the pathogenic TSC1-L117P variant [17] reduced S6K-T389
phosphorylation to a level approximately 3-fold higher than in the
TSC1-TSC2 expressing cells, indicating that this variant can partially
Fig. 6. Immunoblot analysis of TSC1–TSC2 interactions. TSC1 truncation proteins were coexpressed with TSC2 in HEK 293T cells. The truncation proteins were immunoprecipitated
from Triton X100-soluble cell lysate fractions using an anti-myc epitope afﬁnity matrix, and coimmunoprecipitated TSC2 was detected by immunoblotting. Each interaction was
tested at least 3 times. (A and B) Immunoblots showing coimmunoprecipitation of TSC2 with full-length TSC1 and the M351, Q900, R692 and R509 truncations, but not with the
M351-Q900 or T339 truncations, or the myc-tagged β-lactamase control protein (lac). (C) Mean total signal intensity of the immunoprecipitated truncations, relative to full-length
TSC1. Standard deviations are indicated. (D) Mean total signal intensity of coimmunoprecipitated TSC2, relative to the TSC2 signal detected after coimmunoprecipitation with full-
length TSC1. Standard deviations are indicated.
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truncations had a similar effect. In each case, S6K-T389 phosphory-
lation was increased approximately 3-fold with respect to the TSC1–
TSC2 expressing cells, but reduced with respect to cells expressing
TSC2 only. Therefore, in this in vitro assay, the TSC1 R692, M351 and
Q900 truncation proteins all increased the TSC2-dependent inhibition
of S6K-T389 phosphorylation, albeit not as effectively as full-length
TSC1.4. Discussion
TSC1 and TSC2 encode the TSC1–TSC2 protein complex, an essential
regulator of TORC1 [23]. TSC2 contains the active site of the TSC1–TSC2
complex and therefore has a clearly deﬁned functional role. In contrast,
the role of TSC1 is less clear. Some studies suggest that TSC1 is required
for TSC2 GAP activity, while others indicate that TSC1does not affect the
catalytic activity of the TSC1–TSC2 complex, but prevents the
degradation of the complex [7–11]. To gain more insight into the
structure and function of TSC1, we compared the characteristics of a
series of TSC1 truncation proteins with full-length, wild-type TSC1.
We found that deletion of the complete TSC1 coiled coil region
(amino acids 719–998) prevented TSC1 aggregation and that sequences
close to the N-terminal were required for both stability and aggregate
formation. Deletion of amino acids 901–1164, containing the C-terminal
part of the coiled coil region, did not prevent aggregate formation but
did reduce the strength of the TSC1–TSC2 interaction and the activity of
the TSC1–TSC2 complex, consistentwith the identiﬁcation of truncating
mutations in this region of the TSC1 gene in TSC patients [20,21].Deletion of theN-terminal region (amino acids 1–350) had the same
effect on TSC1 expression levels as pathogenic missense changes to this
region [16,17,22]. When one of these mutations (M224R) [17] was
introduced into the R692 truncation protein, the expression level of the
truncation protein was reduced, indicating that the N-terminal region
has an autonomous effect on TSC1 stability. It has been suggested that a
putative transmembrane domain in the N-terminal region of TSC1
(amino acids 127–144) may be important for the correct localisation of
the TSC1–TSC2 complex [12]. One possibility is that recruitment of TSC1
to membranes might help stabilise the TSC1–TSC2 complex. Mutant
TSC1–TSC2 complexes, that are unable to be recruited to themembrane,
might therefore be degraded more rapidly.
To investigate the interactionsbetweenTSC2andtheTSC1 truncation
proteins we performed coimmunoprecipitation experiments. Together,
deletion of the N- and C-terminal regions of TSC1 (amino acids 1–350
and 901–1164) prevented TSC2 binding, while truncation at either
terminal only reduced the interaction, indicating that both theN- and C-
terminal regions of TSC1 are necessary for the formation of stable TSC1–
TSC2 complexes. TheM351 andQ900 truncations thatwere able to bind
TSC2, were also able to promote the TSC2-mediated inhibition of TORC1
activity, asassayedby thephosphorylation status of theTORC1 substrate,
S6K.
Full-length TSC1 coimmunoprecipitated with the R509 and M351-
Q900 truncations, conﬁrming that TSC1 interacts with itself [14], and
indicating that the central region of the protein (amino acids 351–509)
is required for this interaction. In these experiments we only over-
expressed TSC1 and the TSC1 truncations, not TSC2. Furthermore, the
M351-Q900 truncation did not interact with TSC2. Therefore, it is
unlikely that the detected TSC1–TSC1 interactions are a consequence of
Fig. 7. Immunoblot analysis of TSC1–TSC1 interactions. The myc-tagged TSC1
truncations were coexpressed with full-length TSC1 (untagged) in HEK 293T cells.
The truncations were immunoprecipitated from Triton X100-soluble cell lysate
fractions using an anti-myc epitope afﬁnity matrix. Coimmunoprecipitated, untagged
TSC1 was detected by immunoblotting. Each interaction was tested at least 3 times. (A)
Immunoblot showing coimmunoprecipitation of full-length TSC1 with the M351-Q900,
M351, R692 and R509 truncations, but not with the Q900 or T339 truncations, or the
myc-tagged β-lactamase control protein (lac). (B) Mean total signal intensity of the
immunoprecipitated truncations, relative to the β-lactamase control protein (lac).
Standard deviations are indicated. (C) Mean total signal intensity of coimmunopreci-
pitated TSC1, relative to the signal detected after coimmunoprecipitation with the
M351 truncation. Standard deviations are indicated.
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TSC2 subunits. Nevertheless, the TSC1–TSC1 interaction indicates that it
is possible that TSC1–TSC2 complexes consist ofmultiple TSC1 and TSC2
subunits in vivo. It will be interesting to investigate whether substitu-
tions in the central region of TSC1 (amino acids 351–900) disrupt TSC1–
TSC1 binding, and whether such changes can cause the TSC phenotype.
Recently it has beenproposed that different TSC1and TSC2mutations
may result in different neurocognitivemanifestations of TSC, depending
on theexact effects of themutationson the regulationof signalingby the
TSC1–TSC2 complex [24]. One requirement of this hypothesis is that
mutant TSC1 and TSC2 isoforms are expressed. Although all our
experiments were performed in vitro on over-expressed proteins, our
data suggest that if truncated TSC1 isoforms are expressed, then theymay indeed have distinct effects on TSC1–TSC2 function in vivo. Only
limited clinical data were available for the individuals with mutations
corresponding to the truncation proteins analysed.However,we did not
observe any obvious differences between the individuals with a TSC1
c.2295CNT (p.R692X), TSC1 c.2919CNT (p.Q900X) or TSC1 c.1015dupA
(p.T339X) mutation. More work is required to establish whether the
distinct functional characteristics of truncated TSC1 isoforms inﬂuence
the (neurocognitive) phenotype in TSC.
5. Conclusions
The N-terminal region of TSC1 (amino acids 1–350) is required to
stabilise TSC1 and maintain expression levels in the cell. The central
(amino acids 351–509) and C-terminal (amino acids 693–1164)
regions are required for TSC1–TSC1 interactions.
Multiple regions of TSC1, including the N- and C-terminal regions,
are required for binding TSC2, and the binding between truncated
TSC1 proteins and TSC2 is sufﬁcient to promote the ability of TSC2 to
inhibit TORC1 activity in vitro. This information will be useful for the
detailed functional characterisation of unclassiﬁed TSC1 missense
variants identiﬁed in individuals with TSC.
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